A Randomized, Double-blind, Placebo-controlled, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 Sustained-release Tablets in Healthy Subjects
Latest Information Update: 19 Dec 2024
At a glance
- Drugs LY 03015 (Primary)
- Indications Drug-induced dyskinesia; Huntington's disease
- Focus Adverse reactions
- Sponsors Luye Pharma Group
- 12 Dec 2024 Status changed from recruiting to completed.
- 25 Jan 2024 New trial record